Journal of International Psychiatry

Abstract：Objective To investigate the Influence of ziprasidone and paliperidone application on PANSS scores, PRL and body weight of female patients with schizophrenia. Methods 140 female patients with schizophreni were chosen in the period from June 2013 to June 2015 in our hospital and randomly divided into both group including A group (70 patients) with ziprasidone and B group (70 patients) with paliperidone; and the clinical efficacy, the PANSS score, PRL levels and body weight before and after treatment and adverse effects incidence of both groups were compared. Results There was no significant difference in the clinical effects between 2 groups（p>0.05）. The PANSS scores after treatment of both groups were significantly better than before treatment（p<0.05）. There was no significant difference in the PANSS scores after treatment between 2 groups（p>0.05）. The PRL levels after treatment of A group were significantly higher than before treatment（p<0.05）. There was no significant difference in the PRL levels of B group between before and after treatment（p>0.05）. There was no significant difference in the body weight between 2 groups（p>0.05）. There was no significant difference in the adverse effects incidence between 2 groups（p>0.05）. Conclusion Ziprasidone and paliperidone application in the treatment of female patients with schizophrenia possess the same clinical effects and safety; but compared with paliperidone application, Ziprasidone application in the treatment of female patients with schizophrenia can efficiently avoid the impact on the PRL levels of patients and reduce the risk of high serum PRL.

ziprasidone; paliperidone; female; schizophrenia